Extensive analysis shows that the development of therapies based on genomically defined targets have a higher likelihood of success in the clinic.
We use genomics, combined with advances in neuroscience methods and data science, to contribute to the development of safer and more effective medicines for the personalised treatment of mental health and brain disorders.
We work with several university and external partners, including the Medicines Discovery Institute, the Brain Repair and Intracranial Neurotherapeutics Unit, Janssen, and Takeda. The Medicines Discovery Institute and the Brain Repair and Intracranial Neurotherapeutics Unit are unique university assets.
The Medicines Discovery Institute have had success in taking a therapy targeting a synaptic protein for the treatment of cognitive problems in schizophrenia from the laboratory to clinical trials and the Brain Repair and Intracranial Neurotherapeutics Unit is currently developing new ways of treating Huntington’s Disease and is planning the development of a centre of excellence for advanced therapeutics.